DaVita Inc. Schedules 1st Quarter 2022 Investor Conference Call

DENVER, April 21, 2022 /PRNewswire/ -- DaVita Inc. DVA, announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 5, 2022, at 5 p.m. Eastern Time. The company plans to release its results after market close the same day.

This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: 

Thursday, May 5, 2022

Starting at 5 p.m. EDT

Dial in number: 877-918-6630

International dial in: 517-308-9042

Webcast: investors.davita.com

When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the conference call will be able to access a replay via our website at investors.davita.com. There will be no telephone replay.

About DaVita Inc.

DaVita DVA is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of December 31, 2021, DaVita served 203,000 patients at 2,815 outpatient dialysis centers in the United States. The company also operated 339 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Contact Information 

Investors:

IR@davita.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-inc-schedules-1st-quarter-2022-investor-conference-call-301529818.html

SOURCE DaVita Inc.